{"disease":{"id":"recurrent-childhood-central-nervous-system-neoplasm","name":"recurrent childhood central nervous system neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02095132","title":"Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05768880","title":"Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02116777","title":"Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02415153","title":"Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03213691","title":"Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03210714","title":"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00983398","title":"Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":17,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03233204","title":"Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03220035","title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}